Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients

Area of Science:

• Cardiovascular Biology
• Endothelial Cell Biology
• Diabetes Research

Background:

• Endothelial progenitor cell (EPC) function is compromised in diabetes mellitus.
• Aliskiren, a direct renin inhibitor, may influence proangiogenic cells.
• Investigating aliskiren's effect on EPCs from type 2 diabetes mellitus (T2DM) patients is crucial.

Purpose of the Study:

• To determine if aliskiren improves EPC function in T2DM patients.
• To elucidate the mechanisms by which aliskiren affects EPCs.

Main Methods:

• Assessed EPC adhesion, migration, and tube formation in vitro.
• Quantified EPC protein and mRNA expression using Western blot and RT-PCR.
• Utilized siRNA to knockdown vascular endothelial growth factor (VEGF) and (pro)renin receptor ((P)RR) expression.

Main Results:

• Aliskiren dose-dependently enhanced EPC function and increased VEGF and stromal cell-derived factor-1α (SDF-1α) expression.
• VEGF siRNA reduced aliskiren-induced SDF-1α expression.
• (P)RR siRNA impaired aliskiren-induced VEGF and SDF-1α expression.

Conclusions:

• Aliskiren improves T2DM patient EPC function in a dose-dependent manner.
• The mechanism likely involves (P)RR and VEGF/SDF-1α signaling pathways.
• Aliskiren shows potential for improving vascular function in diabetes.